In a strategic step to reinforce its leadership in rare diseases, Chiesi Group has announced the planned acquisition of KalVista Pharmaceuticals in a transaction worth approximately US$1.9 B. The deal provides Chiesi access to KalVista’s Ekterly (sebetralstat), an oral, on-demand therapy approved for hereditary angioedema (HAE), marking a breakthrough in patient convenience compared to injectable options. This acquisition strengthens Chiesi’s rare disease pipeline and expands its US commercial presence, reflecting its long term ambition to broaden its rare immunology offerings and deliver innovative treatments worldwide.